Nouscom Raises $135M to Push Cancer-Preventing Vaccine Into Pivotal Trial

Nouscom has raised $135 million to fund a pivotal trial of its cancer-preventing vaccine candidate, per Fierce Biotech — one of biotech's larger recent rounds.